- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 13, Issue 9, 2007
Current Pharmaceutical Design - Volume 13, Issue 9, 2007
Volume 13, Issue 9, 2007
-
-
Editorial [Hot Topic: Food-Derived Bioactive Proteins and Peptides as Potential Components of Nutraceuticals (Executive Editor: H. Meisel)]
By Hans MeiselIn the last two decades fundamental studies have opened a new field of research related to bioactive food components that not only help ensure adequate nutrition, but may provide specific health benefits [for review: 1]. Bioactive components of food origin can be defined as substances, both nutrient and non-nutrient, which may exert regulative activities in the human organism beyond basic nutrition. In particular, food-derive Read More
-
-
-
Egg Proteins and Peptides in Human Health-Chemistry, Bioactivity and Production
More LessEgg is the largest biological cell known which originates from one cell division and is composed of various important chemical substances that form the basis of life. The avian egg is an important source of nutrients, containing all of the proteins, lipids, vitamins, minerals and growth factors required by the developing embryo, as well as a number of defence factors to protect against bacterial and viral infection. This review Read More
-
-
-
Food-Derived Peptides and Intestinal Functions
Authors: Makoto Shimizu and Dong Ok SonThe intestines are an important organ responsible for nutrient absorption, metabolism and recognition of food signals. The organ also acts as a physical and biological barrier against harmful substances including food pathogens and environmental chemicals. Food-derived peptides with a variety of physiological functions have been discovered in the past several decades. Although dietary peptides would mostly be hydrolyz Read More
-
-
-
Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Authors: Rainer Hartmann, Jean-Michel Wal, Herve Bernard and Anne-Kathrin PentzienThis review article deals with the assessment of cytotoxic and allergenic potential of bioactive proteins and peptides. It is evident that ‘novel’ foods or nutraceuticals containing bioactive proteins and peptides must fulfill their proposed “health claim”. Furthermore, there is a need to assess their potential to exert adverse effects before they can be made widely available to consumers. A brief overview of compounds (i.e. proteins Read More
-
-
-
Nucleoprotein-Derived and Unbound Ribonucleosides: Bioactivity and Potential Applications
Authors: Dierk Martin and Hans MeiselNaturally occurring and chemically modified ribonucleosides have interesting bioactive effects. Dietary ribonucleosides are ingested mainly as nucleoproteins and are converted in the course of intestinal digestion to monomeric compounds. Different bioactive effects of dietary ribonucleosides have been described, including the ability to enhance gut growth and maturation and to increase iron absorption. Cytoc Read More
-
-
-
Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Authors: C. Alarcon de la Lastra, I. Villegas and S. Sanchez-FidalgoPoly(ADP-ribose) polymerase (PARP) comprise of a family of enzymes which catalyses poly(ADPribosyl) ation of DNA-binding proteins. To date, seven isoforms have been identified: PARP-1, PARP-2, PARP-3, PARP- 4 (Vault-PARP), PARP-5 (Tankyrases), PARP-7 and PARP-10 with structural domains and different functions. PARP-1, the best characterised member, works as a DNA damage nick-sensor protein that uses beta-N Read More
-
-
-
Design of New Oxazaphosphorine Anticancer Drugs
Authors: Jun Liang, Min Huang, Wei Duan, Xue-Qing Yu and Shufeng ZhouThe oxazaphosphorines including cyclophosphamide (CPA, Cytoxan, or Neosar), ifosfamide (IFO, Ifex) and trofosfamide (Ixoten) represent an important group of therapeutic agents due to their substantial antitumor and immunomodulating activity. However, several intrinsic limitations have been uncounted during the clinical use of these oxazaphosphorines, including substantial pharmacokinetic variability, resistance and sev Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
